Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200
Polaryx Therapeutics has officially activated the first clinical trial site for its SOTERIA Phase 2 basket trial, which is evaluating the company's lead candidate, PLX-200.